The aim of the work was to analyze the current regulatory legal framework governing the manufacture of drugs in pharmacies, and a comprehensive review of the current state of their manufacture; a disclosure of problems and search for the ways to improve the sphere of circulation of extemporaneously compounded medicines (ECMs).

Materials and methods. The national legislation of the Russian Federation and the regulatory framework of the medicines common market of the Eurasian Economic Union in the field of an extemporaneous drugs circulation formed a regulatory base of the work. To collect and analyze the information data, the materials presented on the official websites of the Ministry of Health of Russia, the Ministry of Industry and Trade of Russia have been used. The results of the scientific publications for the previous 10 years (2014–2024) have also been analyzed.

Results. The article deals with the current state issues of the drug products manufactured in pharmacies, in the sphere of circulation. The analysis of the legislative base on ECMs has been carried out, the problems of the normative legal regulation of the pharmacy drugs manufacturing have been identified. The introduction of new relevant concepts into Federal Law No. 61-FZ “On Circulation of Medicines” — “extemporaneous drug products”, “extemporaneous manufacturing”, “extemporaneous production” — has been proposed. The authors’ definition of the “pharmaceutical sovereignty” concept was given in the course of the study. Based on the results of the study, the possibilities and ways of improving the mechanisms of the state regulation of the drugs extemporaneous manufacturing in the current political and economic conditions have been identified.

Conclusion. The operational management and systematization of the regulatory legal framework of the ECMs circulation sphere based on the regulatory science is the most important factor in increasing the affordable, effective, personalized pharmaceutical care. An important element of the mobilization model of the economy is strengthening of the state regulation, development of the domestic production capacities and technologies, including taking into account extemporaneous manufacturing of drugs and small-scale production.

The aim of the work was to collect and systematize the data on the treatment approaches to pulmonary lymphangioleiomyomatosis (LAM) based on insights into the pathogenesis of the disease.

Materials and methods. 70 original sources have been selected from analyzed 1 157 articles and monographs (including duplicates). The search for the sources was carried out in the databases of PubMed, eLibrary.ru, Cyberleninka for a fifty-year period of publications (from 1973 to August 2023), with an emphasis on more current publications and the ones in highly rated scientific journals.

Results. The review presents the treatment approaches to LAM, based both on clinical observations of the disease course and on the experimental data on its probable pathogenesis. The collected data are presented in the chronological order, starting from radical methods based on the idea of an unconditional connection between the development of LAM and the female sex hormones. Special attention has been paid to the drugs from the group of mTOR inhibitors, including their safety profile. In addition, the results of the studies demonstrating new promising methods of the LAM drug therapy, both combining the use of mTOR inhibitors with other drugs, and the ones based on the isolated use of alternative groups of drugs, are presented in the work.

Conclusion. The currently used methods of the drug therapy and the proposed new methods are aimed at only treating an already established disease, and the effective drug prevention of LAM now seems almost impossible due to the lack of a complete understanding about its pathogenesis and, more importantly, its etiology. This issue is the most relevant in determining further prospects for the development of pharmacotherapeutic approaches to LAM.

Compliance with the recommendations of a health professional by patients with chronic diseases is observed only in 50% of cases, and therefore, the problem of compliance is very relevant. The widespread occurrence of osteoporosis (OP) in Russia and the world, as well as the existing problem of reducing patient compliance, requires an analysis of existing data on the level of treatment adherence in patients with OP.

The aim. To analyze the current state of adherence to therapy in patients with OP.

Materials and methods. The article provides an overview of the available publications on the mentioned objective. Various databases and search engines were used to search for research by Russian and foreign authors: elibrary.ru, CyberLeninka, Russian National Library (RNB), PubMed, Scientific&Scholarly Research Database (Scilit), Google Academy. The information was searched by keywords and phrases: “osteoporosis”, “osteoporosis”, “adherence to therapy/treatment”, “adherence to treatment”, “compliance”, “compliance”, as well as the corresponding MeSH terms.

Results. The current state of the OP problem has been studied, and the pharmacotherapy currently used in this pathology has been considered. The data on the compliance of patients with OP, the factors that negatively affect the adherence of patients, as well as the methods that contribute to the growth of this indicator, are analyzed, and the expediency of their use is demonstrated.

Conclusion. The problem of adherence to treatment of patients with OP is an important issue of modern healthcare. One of the most effective ways to improve compliance is to increase patients’ awareness of the disease, its course, methods and expediency of pharmacotherapy. There is an urgent need to develop accessible and search for new methods to increase treatment adherence in patients with OP.

The aim. To evaluate the results of clinical studies on the efficacy and safety of bronchial asthma (BA) therapy with genetically engineered biologicals (GEBP) in children and adolescents.

Materials and methods. For writing this review article, a search for full-text publications was conducted in the PubMed database. Studies on the efficacy and safety of biologicals — monoclonal antibodies, in the treatment of BA refractory to therapy with inhaled glucocorticosteroids and beta-2-agonists, in children and adolescents from 2010 to 2025 were analyzed using the following key queries”bronchial asthma”, “monoclonal antibodies”, “anti-IgE antibody”, “anti-IL-receptor antibody”, “anti-thymic stromal lymphopoietin antibody”, “adolescents”, “children”.

Results. The observed continuing and steady increase in the incidence of BA, the involvement of several organ systems in the pathological process, the difficulty in choosing treatment tactics, the high cost of therapy, and the need to monitor the patient’s condition place this disease in a special place among modern medical problems. To date, advances in genetic engineering have made it possible to introduce GEBPs — monoclonal antibody drugs, into medical practice as one of the steps in the treatment of poorly controlled and resistant to first-line therapy BA of moderate and severe severity. According to recent clinical studies among children and adolescents, biologicals to varying degrees can affect symptom control, lung function, frequency of exacerbations, requests for emergency medical care and hospitalizations, as well as reducing the dosages of glucocorticosteroids and beta-2-agonists used.

Conclusion. To date, positive results have been noted in the use of monoclonal antibodies in the treatment of BA, but clinical trial data among children and adolescents are limited. There is also insufficient information about the consequences of the mechanism of influence of these drugs in relation to long-term inhibition of the immune system and a decrease in the content of eosinophils in the blood serum in the developing child’s body. To formulate a final conclusion, further study of the long-term efficacy and safety of biologicals in pediatric practice is necessary in order to combat this serious public threat.